FY2026 EPS Estimates for Adicet Bio Boosted by HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET) – Equities researchers at HC Wainwright increased their FY2026 EPS estimates for shares of Adicet Bio in a research report issued on Friday, November 6th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($7.62) per share for the year, up from their previous forecast of ($8.05). HC Wainwright currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($6.76) per share. HC Wainwright also issued estimates for Adicet Bio’s Q4 2026 earnings at ($1.99) EPS, Q1 2027 earnings at ($2.10) EPS, Q2 2027 earnings at ($1.88) EPS, Q3 2027 earnings at ($1.71) EPS, Q4 2027 earnings at ($1.77) EPS and FY2027 earnings at ($7.39) EPS.

Adicet Bio (NASDAQ:ACET) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.20).

A number of other research firms have also commented on ACET. Jefferies Financial Group raised Adicet Bio to a “strong-buy” rating in a research report on Tuesday, September 1st. Guggenheim reissued a “buy” rating and set a $90.00 target price (down from $100.00) on shares of Adicet Bio in a research note on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adicet Bio in a report on Friday, August 21st. Benchmark restated a “buy” rating on shares of Adicet Bio in a report on Tuesday, September 29th. Finally, Wall Street Zen lowered shares of Adicet Bio from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Adicet Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.80.

Adicet Bio Stock Down 2.0%

Shares of Adicet Bio stock opened at $2.99 on Tuesday. Adicet Bio has a 1 year low of $2.87 and a 1 year high of $11.20. The business has a 50-day moving average of $6.43 and a two-hundred day moving average of $7.54. The company has a market capitalization of $27.99 million, a P/E ratio of -0.35 and a beta of 1.69. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.71 and a quick ratio of 6.71.

Institutional Trading of Adicet Bio

Several hedge funds and other institutional investors have recently modified their holdings of ACET. NewEdge Advisors LLC acquired a new position in Adicet Bio in the 1st quarter valued at about $26,000. Dimensional Fund Advisors LP acquired a new position in shares of Adicet Bio in the first quarter valued at approximately $73,000. AXQ Capital LP acquired a new position in shares of Adicet Bio in the second quarter valued at approximately $95,000. Squarepoint Ops LLC acquired a new position in shares of Adicet Bio in the second quarter valued at approximately $132,000. Finally, Johnson & Johnson bought a new position in shares of Adicet Bio during the second quarter worth approximately $196,811. Institutional investors and hedge funds own 83.89% of the company’s stock.

Adicet Bio Company Profile

Adicet Bio, Inc is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. The company’s platform is focused on genetically engineered gamma delta T cells, an immune-cell type that can recognize and attack abnormal cells while potentially offering advantages for off-the-shelf cell therapy development.

Adicet’s product candidates are designed to incorporate chimeric antigen receptors and other modifications intended to improve tumor targeting, persistence, and activity.